Payment overview · 2025
General Payments
$973.52
54 reported records · 19 companies
Healthcare provider profile · identity verified
Thomas O Borgstedte, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LA GRANGE, TX · NPI 1295877264
Verified facts
What the public records show
CMS Open Payments records show Thomas O Borgstedte, D.O. received $973.52 in general payments during 2025 across 54 reported records.
Amgen Inc. accounted for 15.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Shingrix, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.77 | 15.4% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $137.80 | 14.2% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $135.16 | 13.9% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $108.45 | 11.1% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $79.70 | 8.2% | 3 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $58.23 | 6.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.76 | 5.5% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $41.55 | 4.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $30.33 | 3.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.85 | 2.9% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $21.51 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.04 | 2.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.59 | 1.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.11 | 1.8% | 1 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $15.69 | 1.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.86 | 1.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.73 | 1.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.46 | 1.5% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $13.93 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $949.94 | 52 |
| Entertainment | $13.93 | 1 |
| Education | $9.65 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $139.49 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $135.16 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $104.73 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $97.00 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $79.70 | 3 | 2025 |
Source payment records
|
|||||
| MONOVISC Normalized: monovisc |
Device | DePuy Synthes Sales Inc. | $58.23 | 2 | 2025 |
Source payment records
|
|||||
| ORTHOVISC Normalized: orthovisc |
Device | DePuy Synthes Sales Inc. | $58.23 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.71 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $41.55 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.07 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $30.33 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.85 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.71 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Zilretta Normalized: zilretta |
Drug | Pacira Pharmaceuticals Incorporated | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $12.00 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $11.42 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $10.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 170 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 103 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 67 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
170 | 33 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
234 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
103 | 87 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 972 | 256 |
| Levothyroxine Sodium | Levothyroxine Sodium | 790 | 178 |
| Losartan Potassium | Losartan Potassium | 603 | 153 |
| Gabapentin | Gabapentin | 592 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 561 | 150 |
| Lisinopril | Lisinopril | 445 | 118 |
| Pantoprazole Sodium | Pantoprazole Sodium | 427 | 103 |
| Omeprazole | Omeprazole | 371 | 94 |
| Potassium Chloride | Potassium Chloride | 357 | 76 |
| Fluticasone Propionate | Fluticasone Propionate | 344 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 342 | 86 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 329 | 78 |
| Furosemide | Furosemide | 321 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 321 | 81 |
| Sertraline Hcl | Sertraline Hcl | 294 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 77 |
| Metformin Hcl | Metformin Hcl | 272 | 62 |
| Trazodone Hcl | Trazodone Hcl | 262 | 53 |
| Ezetimibe | Ezetimibe | 238 | 63 |
| Eliquis | Apixaban | 234 | 36 |
| Alprazolam | Alprazolam | 221 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 210 | 58 |
| Donepezil Hcl | Donepezil Hcl | 206 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 198 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 196 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 190 | 44 |
| Metformin Hcl Er | Metformin Hcl | 187 | 49 |
| Carvedilol | Carvedilol | 186 | 42 |
| Tramadol Hcl | Tramadol Hcl | 186 | 41 |
| Famotidine | Famotidine | 178 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 43 |
| Allopurinol | Allopurinol | 173 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 170 | 34 |
| Jardiance | Empagliflozin | 170 | 33 |
| Simvastatin | Simvastatin | 167 | 38 |
| Celecoxib | Celecoxib | 161 | 30 |
| Mounjaro | Tirzepatide | 157 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 153 | 25 |
| Finasteride | Finasteride | 147 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 30 |
| Montelukast Sodium | Montelukast Sodium | 142 | 45 |
| Pregabalin | Pregabalin | 140 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 139 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 43 |
| Clonazepam | Clonazepam | 133 | 21 |
| Ozempic | Semaglutide | 131 | 20 |
| Memantine Hcl | Memantine Hcl | 128 | 22 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 124 | 123 |
| Mirtazapine | Mirtazapine | 112 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 25 |
| Lorazepam | Lorazepam | 105 | 27 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 103 | 87 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 27 |
| Meloxicam | Meloxicam | 98 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 97 | 19 |
| Alendronate Sodium | Alendronate Sodium | 88 | 18 |
| Valsartan | Valsartan | 87 | 27 |
| Azelastine Hcl | Azelastine Hcl | 86 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 16 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 80 | suppressed |
| Aripiprazole | Aripiprazole | 79 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 79 | 79 |
| Buspirone Hcl | Buspirone Hcl | 79 | 13 |
| Farxiga | Dapagliflozin Propanediol | 79 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 74 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 12 |
| Synthroid | Levothyroxine Sodium | 67 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 14 |
| Lamotrigine | Lamotrigine | 64 | suppressed |
| Repatha Sureclick | Evolocumab | 64 | 14 |
| Torsemide | Torsemide | 64 | 15 |
| Methocarbamol | Methocarbamol | 63 | 23 |
| Prednisone | Prednisone | 63 | 20 |
| Bupropion Xl | Bupropion Hcl | 61 | 14 |
| Trulicity | Dulaglutide | 61 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 60 | 11 |
| Atenolol | Atenolol | 58 | 16 |
| Spironolactone | Spironolactone | 58 | 20 |
| Estradiol | Estradiol | 57 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 55 | suppressed |
| Temazepam | Temazepam | 51 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | suppressed |
| Cephalexin | Cephalexin | 48 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 16 |
| Nystatin | Nystatin | 47 | 27 |
| Primidone | Primidone | 45 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Praluent Pen | Alirocumab | 43 | suppressed |
| Topiramate | Topiramate | 43 | suppressed |
| Ketoconazole | Ketoconazole | 42 | 11 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Lovastatin | Lovastatin | 42 | suppressed |
| Mupirocin | Mupirocin | 42 | 13 |
| Oxcarbazepine | Oxcarbazepine | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 29 |
| Azithromycin | Azithromycin | 38 | 34 |
| Diazepam | Diazepam | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Ciclopirox | Ciclopirox | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | 12 |
| Verapamil Sr | Verapamil Hcl | 32 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 13 |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Lacosamide | Lacosamide | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 20 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Risperidone Odt | Risperidone | 25 | suppressed |
| Fanapt | Iloperidone | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 20 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Sotalol Af | Sotalol Hcl | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Clobazam | Clobazam | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $973.52 · 54 records | Amgen Inc. | AIRSUPRA, BEXSERO, CAPLYTA, CAPVAXIVE, COBENFY, Dexcom G6 Transmitter, ENFLONSIA, EVENITY, FARXIGA, GARDASIL 9, INTELLIS ADAPTIVESTIM, JARDIANCE, Korlym, LEQVIO, MONOVISC, NEXLETOL, NFC-700, OCT OPHTHALMOSCOPE, ORTHOVISC, OTEZLA, PANORAMIC OPHTHALMOSCOPE, QULIPTA, REPATHA, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, XYOSTED, Zilretta, bio-ConneKt | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error